DNAJC17

Across TCGA pan-cancer cohorts, DNAJC17 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DNAJC17 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DNAJC17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DNAJC17 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

HNSC, LUAD, and COAD are the cancer types where DNAJC17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.166	0.973	.010	50	view →
LUAD	DFS	Quartile	II,III,IV	0.789	0.885	.014	18	view →
COAD	DFS	Tertile	II,III,IV	0.914	1.000	.035	12	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	6	view →
LSCC	OS	Median	III,IV	0.686	0.990	.035	3	view →
PDAC	DFS	Median	All	0.354	0.224	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DNAJC17–HNSC (OS)

Open the HNSC breakdown →